• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, April 12, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Protein identified as potential druggable target for pancreatic cancer

Bioengineer by Bioengineer
March 28, 2017
in Science News
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: MD Anderson Cancer Center

HOUSTON – A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling.

"Our study has identified and validated for the first time an arginine methyltransferase as a novel genetic vulnerability in PDAC," said Giulio Draetta, M.D., Ph.D., professor of Genomic Medicine and director of Institute for Applied Cancer Science (IACS) at The University of Texas MD Anderson Cancer Center. "These findings strongly suggest a role for PRMT1 in PDAC development and illuminate a path toward the development of therapies for patients in desperate need of innovative solutions."

Results from the study will be reported April 3 at the annual meeting of the American Association for Cancer Research in Washington, D.C.

Various treatment regimens have failed to improve PDAC patient survival, driving the critical need for finding druggable targets essential for tumor maintenance. Draetta's team developed an in vivo platform called Patient-based In vivo Lethality to Optimize Treatment (PILOT), a technology enabling systemic identification of tumor vulnerabilities in patient-derived tumors. Through PILOT, they discovered novel epigenetic drivers in PDAC, including PRMT1 in tumors that harbor KRAS mutations on the background of p53. KRAS and p53 are genes often associated with cancer.

"Through this assessment of epigenetic regulators, we identified PRMT1 as a top scoring 'hit' in these patient-derived tumors," said Virginia Giuliani, Ph.D., senior research scientist, IACS. "This novel dependency was subsequently validated in multiple patient-derived pancreas models."

The team confirmed that genetic "knockdown" of PRMT1 significantly impaired PDAC cell growth in vitro through use of genetic editing tools, including CRISPR and small hairpin RNA (shRNA). This correlated with a global reduction in arginine methylation, which controls multiple cellular processes, including DNA replication and DNA repair.

"We also confirmed a role in PDAC tumor maintenance as inhibition of PRMT1 in patient-derived mouse models significantly inhibited tumor growth and extended survival," said Giuliani. "These data suggest that small molecule inhibition of PRMT1 could be an impactful therapeutic strategy in pancreas cancer."

The teams at MD Anderson's and Center for Co-Clinical Trials are using the PILOT platform to investigate novel vulnerabilities across tumor subtypes with the aim of identifying targets for therapeutic development. PRMT1 is one of several epigenetic dependencies that have been identified using this approach.

###

The study was supported by philanthropic contributions to MD Anderson's Moon Shots Program™ and the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer.

IACS study team members included Bhavatarini Vangamudi, Ph.D., Erika Suzuki, Ph.D., Meredith Miller, Ph.D., Chiu-yi Liu, Ph.D., Alessandro Carugo, Ph.D., Christopher Bristow, Ph.D., Guang Gao, Ph.D., Jing Han, Ph.D., Yuting Sun, Ph.D., Ningping Feng, Ph.D., Edward Chang, Ph.D., Joseph Marszalek, Ph.D., Jeffrey Kovacs, Ph.D., Maria Emilia Di Francesco, Ph.D., Carlo Toniatti, M.D., Ph.D., Timothy Heffernan, Ph.D., and Philip Jones, Ph.D.

Media Contact

Ron Gilmore
[email protected]
713-745-1898
@mdandersonnews

http://www.mdanderson.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

April 11, 2021
IMAGE

Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling

April 10, 2021

Level of chromosomal abnormality in lung cancer may predict immunotherapy response

April 10, 2021

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

April 10, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    851 shares
    Share 340 Tweet 213
  • Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    59 shares
    Share 24 Tweet 15
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14
  • A sturdier spike protein explains the faster spread of coronavirus variants

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Cell BiologyGeneticsMedicine/HealthClimate ChangeInfectious/Emerging DiseasesTechnology/Engineering/Computer SciencePublic HealthMaterialscancerEcology/EnvironmentChemistry/Physics/Materials SciencesBiology

Recent Posts

  • MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
  • Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling
  • Level of chromosomal abnormality in lung cancer may predict immunotherapy response
  • Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In